Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung Health Condition 2: null- stage 2b and 3 Non Small Cell Lung Cancer
Conditions
Interventions
Intervention1: Inj. paclitaxel, Inj. Carboplatin: INJ. Paclitaxel 80 mg/m2 day 1,8,15
Inj. Carboplatin AUC 6 Day 1
Q 3 weekly
Control Intervention1: NA: NA
Control Intervention2: NA: NA
Sponsors
investigator initiated study
Eligibility
Inclusion criteria
Inclusion criteria: 1. Pathological diagnosis of NSCLC 2. Age 18 to 75 years 3. ECOG PS 0-2 4. Local disease T3 (with > 5cm contact with chest wall) or T4 5. Mediastinal stage N0, N1 or non bulky N2 (defined as single station N2 station node
Exclusion criteria
Exclusion criteria: 1. ECOG PS >2 2. Gross mediastinal structures invasion 3. SVCO 4. Immunocompromised 5. Multiple comorbidities precluding possibilty of surgery 6. Poor PFT (predicted post operative FEV1 7. Pregnent and lactating females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| oRdiological response rates with neoadjuvant chemotherapyTimepoint: At the end of Four cycle of chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Improvement in resectability, (pnemonectomy converted to conservative surgery) 2.Toxicity profile assessment 3.Progression free survival (from date of enrollment till date of disease progression or death ) 4.Post operative/ operarive complications Timepoint: 1. At the end of neoadjuvent chemotherapy. 2. At the end of the therapy. | — |
Countries
India
Contacts
Public ContactPrabhat Singh Malik
Dr.B.R.A.I.R.C.H., All India Institute of Medical Sciences
Outcome results
None listed